Printer Friendly

MTF, Aastrom form partnership to develop novel treatments for tissue regeneration.

The Musculoskeletal Transplant Foundation (MTF), Edison, NJ, and Aastrom Biosciences, Inc., Ann Arbor, MI, announced they have formed a strategic alliance to jointly develop and commercialize innovative treatments for the regeneration of tissues such as bone and cartilage. The companies report they will initially focus on combining their respective technologies to establish a novel treatment approach for bone graft applications.

Under terms of the alliance, the companies will provide each other with rights to their respective technologies for treatments and products that are based on combinations of MTF's matrices and Aastrom's Tissue Repair Cells (TRCs). The companies say they will share in the development and clinical trial expense of the treatment approaches and products, and will adopt a coordinated promotion and marketing strategy for future products. In addition to bone graft applications, the companies will explore new approaches for the regeneration of joint cartilage, as well as effective combinations of TRCs with MTF's new ceramic matrix technology.

The market for these applications is estimated at more than 1.4 million procedures annually, including spinal fusions, non-union fractures, dental defects and facial bone repair.

Contact: Tom Shaffer, MTF - (800) 946-9008, ext. 2522, or Kris Maly, Aastrom - (734) 930-5777. Web sites: www.mtf.org, and www.aastrom.com.
COPYRIGHT 2003 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Musculoskeletal Transplant Foundation, Aastrom Biosciences Inc.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 14, 2003
Words:206
Previous Article:Bionic eye can restore some sight to the blind.
Next Article:FDA to allow Anamed to expand Phase II study of its PermaVision Intracorneal lens.
Topics:


Related Articles
MTF, Regeneration Technologies withdraw all charges, dismiss lawsuits filed in June 2001.
Aastrom Biosciences signs agreement with Mathys Medical for German bone graft clinical trial.
Aastrom Biosciences receives culture device European patent.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.
Aastrom receives patent expanding coverage for its single-pass perfusion technology.
Aastrom received FDA approval to initiate multi-center trial for bone graft product.
Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters